

# Davide Festi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2171541/publications.pdf>

Version: 2024-02-01

171  
papers

8,132  
citations

53751

45  
h-index

54882

84  
g-index

177  
all docs

177  
docs citations

177  
times ranked

8833  
citing authors

#	ARTICLE	IF	CITATIONS
1	Size and location of spontaneous portosystemic shunts predict the risk of decompensation in cirrhotic patients. <i>Digestive and Liver Disease</i> , 2022, 54, 103-110.	0.4	22
2	Validation of a standardized CT protocol for the evaluation of varices and porto-systemic shunts in cirrhotic patients. <i>European Journal of Radiology</i> , 2022, 147, 110010.	1.2	13
3	Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia. <i>Cancer Medicine</i> , 2022, 11, 618-629.	1.3	3
4	Sarcopenia Predicts Major Complications after Resection for Primary Hepatocellular Carcinoma in Compensated Cirrhosis. <i>Cancers</i> , 2022, 14, 1935.	1.7	14
5	Comparison of screening strategies with two new tests to score and diagnose varices needing treatment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101925.	0.7	2
6	Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 777-787.e17.	2.4	19
7	Distinguishing features between patients with acute diverticulitis and diverticular bleeding: Results from the REMAD registry. <i>Digestive and Liver Disease</i> , 2021, 53, 202-209.	0.4	5
8	Gut microbiota signatures and clinical manifestations in celiac disease children at onset: a pilot study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 446-454.	1.4	37
9	Clinical impact of sarcopenia assessment in patients with liver cirrhosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 377-388.	1.4	15
10	The Assessment of Portal Hypertension. , 2021, , 159-171.		0
11	Imaging Software-Based Sarcopenia Assessment in Gastroenterology: Evolution and Clinical Meaning. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-7.	0.8	8
12	A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study. <i>Cancers</i> , 2021, 13, 2677.	1.7	6
13	Prognostic Value of the Albumin-Bilirubin Grade for the Prediction of Post-Hepatectomy Liver Failure: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2011.	1.0	16
14	The role of liver and spleen elastography in advanced chronic liver disease. <i>Minerva Gastroenterology</i> , 2021, 67, 151-163.	0.3	4
15	Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness. <i>JHEP Reports</i> , 2021, 3, 100289.	2.6	12
16	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.. <i>Digestive and Liver Disease</i> , 2021, 53, 1011-1019.	0.4	7
17	Clinical Presentation of Celiac Disease and Diagnosis Accuracy in a Single-Center European Pediatric Cohort over 10 Years. <i>Nutrients</i> , 2021, 13, 4131.	1.7	0
18	A novel spleenâ€dedicated stiffness measurement by FibroScanÂ® improves the screening of highâ€risk oesophageal varices. <i>Liver International</i> , 2020, 40, 175-185.	1.9	60

#	ARTICLE	IF	CITATIONS
19	Spleen Stiffness Measurements Predict the Risk of Hepatic Decompensation After Direct-Acting Antivirals in HCV Cirrhotic Patients. <i>Ultraschall in Der Medizin</i> , 2020, , .	0.8	15
20	Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments. <i>Journal of Gastroenterology</i> , 2020, 55, 927-943.	2.3	70
21	Is Ultrasound Elastography Useful in Predicting Clinically Relevant Pancreatic Fistula After Pancreatic Resection?. <i>Pancreas</i> , 2020, 49, 1342-1347.	0.5	4
22	Probiotics, Prebiotics and Other Dietary Supplements for Gut Microbiota Modulation in Celiac Disease Patients. <i>Nutrients</i> , 2020, 12, 2674.	1.7	47
23	Clinical outcomes after treatment with direct-acting antivirals: not all concern hepatocellular carcinoma risk. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 505-507.	0.7	3
24	A novel nomogram based on liver stiffness to predict the comprehensive complication index after liver resection in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, S259-S260.	1.8	0
25	The prevalence of esophageal varices needing treatment depends on gender, etiology and BMI. <i>Journal of Hepatology</i> , 2020, 73, S751-S752.	1.8	1
26	Spleen stiffness measurement for assessing the response to $\beta$ -blockers therapy for high-risk esophageal varices patients. <i>Hepatology International</i> , 2020, 14, 850-857.	1.9	41
27	Ablation for hepatocellular carcinoma: beyond the standard indications. <i>Medical Oncology</i> , 2020, 37, 23.	1.2	7
28	A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, 855-862.	1.8	67
29	Adverse Food Reaction and Functional Gastrointestinal Disorders: Role of the Dietetic Approach. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 319-327.	0.5	11
30	Curcumin and Fennel Essential Oil Improve Symptoms and Quality of Life in Patients with Irritable Bowel Syndrome. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 25, 151-157.	0.5	62
31	Non-invasive tests for the prediction of primary hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2020, 26, 3326-3343.	1.4	28
32	How to clarify the Baveno <sc>VI</sc> criteria for ruling out varices needing treatment by noninvasive tests. <i>Liver International</i> , 2019, 39, 49-53.	1.9	21
33	FRI-290-The role of bile acids profile and insulin reistance for the prediction of gallstone disease in a prospective cohort of blood donors. <i>Journal of Hepatology</i> , 2019, 70, e523.	1.8	0
34	Liver Stiffness Measurement Allows Early Diagnosis of Venous Occlusive Disease/Sinusoidal Obstruction Syndrome in Adult Patients Who Undergo Hematopoietic Stem Cell Transplantation: Results from a Monocentric Prospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 995-1003.	2.0	56
35	Reply to correspondence concerning: "Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection". <i>Journal of Hepatology</i> , 2019, 70, 809-810.	1.8	2
36	Longitudinal evaluation of liver stiffness in three pediatric patients with venous occlusive disease. <i>Pediatric Transplantation</i> , 2019, 23, e13456.	0.5	13

#	ARTICLE	IF	CITATIONS
37	Role of imaging techniques in liver veno-occlusive disease diagnosis: recent advances and literature review. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 463-484.	1.4	34
38	Nerve fiber overgrowth in patients with symptomatic diverticular disease. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13575.	1.6	14
39	Liver and Spleen Stiffness Measurements for Assessment of Portal Hypertension Severity in Patients with Budd Chiari Syndrome. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-6.	0.8	22
40	Prediction of posthepatectomy liver failure: Role of SSM and LSPS. <i>Journal of Surgical Oncology</i> , 2019, 119, 400-401.	0.8	10
41	“Are the Expanded Baveno VI Criteria really safe to screen compensated cirrhotic patients for high-risk varices?” <i>Digestive and Liver Disease</i> , 2019, 51, 456-457.	0.4	12
42	Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection. <i>Journal of Hepatology</i> , 2019, 70, 440-448.	1.8	126
43	Interleukin 28 Polymorphisms and Hepatocellular Carcinoma Development after Direct Acting Antiviral Therapy for Chronic Hepatitis C. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 449-456.	0.5	10
44	Vascular and Parenchymal Alterations of the Liver and Liver Surveillance in Patients Who Received Inotuzumab Ozogamicin As the Standard of Care for Relapse/Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 1343-1343.	0.6	1
45	Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals. <i>Digestive and Liver Disease</i> , 2018, 50, 573-579.	0.4	56
46	Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1268-1275.e2.	2.4	42
47	A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease. <i>Journal of Hepatology</i> , 2018, 69, 308-317.	1.8	142
48	A Novel FibroScan Examination Dedicated to Spleen Stiffness Measurement. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 1616-1626.	0.7	27
49	Spleen Stiffness by Ultrasound Elastography. , 2018, , 113-137.		7
50	Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-11.	0.7	46
51	Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients. <i>World Journal of Hepatology</i> , 2018, 10, 731-742.	0.8	24
52	Transient Elastography Anticipates the Diagnosis of VOD/SOS after Adult Allogeneic Stem Cell Transplant: Results from a Prospective Study. <i>Blood</i> , 2018, 132, 2098-2098.	0.6	0
53	Adding Liver Stiffness Measurement to the Routine Evaluation of Hepatocellular Carcinoma Resectability Can Optimize Clinical Outcome. <i>Ultraschall in Der Medizin</i> , 2017, 38, 515-522.	0.8	3
54	Sulfasalazine in Prevention of Pouchitis After Proctocolectomy with Ileal Pouch–Anal Anastomosis for Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1016-1024.	1.1	19

#	ARTICLE	IF	CITATIONS
55	Primary biliary cholangitisâ€“primary sclerosing cholangitis in an evolving overlap syndrome: A case report. <i>Gastroenterology</i> & <i>Hepatology</i> , 2017, 40, 669-671.	0.2	8
56	Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease. <i>Gut</i> , 2017, 66, 1252-1261.	6.1	138
57	Ductal stones recurrence after extracorporeal shock wave lithotripsy for difficult common bile duct stones: Predictive factors. <i>Digestive and Liver Disease</i> , 2017, 49, 1128-1132.	0.4	2
58	Differences in liver stiffness values obtained with new ultrasound elastography machines and Fibroscan: A comparative study. <i>Digestive and Liver Disease</i> , 2017, 49, 802-808.	0.4	51
59	Relationship between indocyanine green retention test, decompensation and survival in patients with Childâ€“Pugh A cirrhosis and portal hypertension. <i>Liver International</i> , 2016, 36, 1313-1321.	1.9	29
60	MRI Patterns in a Case of 6-Thioguanine-Related Hepatic Sinusoidal Obstruction Syndrome. <i>American Journal of Gastroenterology</i> , 2016, 111, 767.	0.2	7
61	Are Noninvasive Methods Clinically Useful in Advanced, Decompensated Liver Cirrhosis When â€œLes Jeux Sont Faitsâ€?. <i>Radiology</i> , 2016, 278, 304-306.	3.6	2
62	Gut Microbiota and Celiac Disease. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1461-1472.	1.1	115
63	Pathophysiology and Therapeutic Strategies for Symptomatic Uncomplicated Diverticular Disease of the Colon. <i>Digestive Diseases and Sciences</i> , 2016, 61, 673-683.	1.1	25
64	Clinical application of faecal calprotectin in ulcerative colitis patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 1418-1424.	0.8	24
65	Liver and spleen stiffness and other noninvasive methods to assess portal hypertension in cirrhotic patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 992-1001.	0.8	51
66	Reply to Letter. <i>Annals of Surgery</i> , 2015, 261, e105-e106.	2.1	1
67	Simultaneous Analysis of SEPT9 Promoter Methylation Status, Micronuclei Frequency, and Folate-Related Gene Polymorphisms: The Potential for a Novel Blood-Based Colorectal Cancer Biomarker. <i>International Journal of Molecular Sciences</i> , 2015, 16, 28486-28497.	1.8	21
68	Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1039-1053.	1.4	13
69	Enlarged pancreas: not always a cancer. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2015, 14, 107-108.	0.6	4
70	Risk Factors for Gallstone Formation During Weight Loss. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 613.	2.4	8
71	Dysbiosis in Celiac Disease Patients With Persistent Symptoms on Gluten-Free Diet: A Condition Similar to that Present in Irritable Bowel Syndrome Patients?. <i>American Journal of Gastroenterology</i> , 2015, 110, 598.	0.2	11
72	Gut microbiota and metabolic syndrome. <i>World Journal of Gastroenterology</i> , 2014, 20, 16079.	1.4	405

#	ARTICLE	IF	CITATIONS
73	Prognostic factors for hepatocellular carcinoma recurrence. <i>World Journal of Gastroenterology</i> , 2014, 20, 5935.	1.4	143
74	Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis. <i>Hepatology</i> , 2014, 59, 643-650.	3.6	91
75	Micronucleus frequency in human peripheral blood lymphocytes as a biomarker for the early detection of colorectal cancer risk. <i>Mutagenesis</i> , 2014, 29, 221-225.	1.0	31
76	Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: A prospective study. <i>Journal of Hepatology</i> , 2014, 60, 1158-1164.	1.8	123
77	Italian consensus conference for colonic diverticulosis and diverticular disease. <i>United European Gastroenterology Journal</i> , 2014, 2, 413-442.	1.6	141
78	A new point-of-care portable immunosensor for non-invasive assessment of oro-ileal transit time by oral fluid tauroursodeoxycholate measurement after its oral load. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013, 81-82, 1-7.	1.4	1
79	Review article: the diagnosis of non-alcoholic fatty liver disease – availability and accuracy of non-invasive methods. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 392-400.	1.9	156
80	Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 656-657.	1.9	6
81	Focal nodular hyperplasia of the liver in children after hematopoietic stem cell transplantation. <i>Pediatric Transplantation</i> , 2013, 17, 479-486.	0.5	16
82	Telbivudine treatment for fulminant HBV hepatitis. <i>Journal of Digestive Diseases</i> , 2013, 14, n/a-n/a.	0.7	1
83	Benign Hepatic Nodular Lesions After Treatment for Childhood Cancer. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2013, 56, 151-155.	0.9	16
84	Non-invasive panel tests for gastrointestinal motility monitoring within the MARS-500 Project. <i>World Journal of Gastroenterology</i> , 2013, 19, 2208.	1.4	10
85	Value of Transient Elastography Measured With Fibroscan in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2012, 256, 706-713.	2.1	142
86	Noninvasive Parameters for Predicting Esophageal Varices in Children: Their Sequential Use Provides the Best Accuracy. <i>Gastroenterology</i> , 2012, 142, e32.	0.6	3
87	Measurement of Spleen Stiffness to Evaluate Portal Hypertension and the Presence of Esophageal Varices in Patients With HCV-Related Cirrhosis. <i>Gastroenterology</i> , 2012, 143, 646-654.	0.6	440
88	Relationship between hepatic haemodynamics assessed by Doppler ultrasound and liver stiffness. <i>Digestive and Liver Disease</i> , 2012, 44, 154-159.	0.4	18
89	Coeliac disease and autoimmune hepatitis: Gluten-free diet can influence liver disease outcome. <i>Digestive and Liver Disease</i> , 2011, 43, 247.	0.4	7
90	Non-invasive methods can predict oesophageal varices in patients with biliary atresia after a Kasai procedure. <i>Digestive and Liver Disease</i> , 2011, 43, 659-663.	0.4	41

#	ARTICLE	IF	CITATIONS
91	Pre-operative liver biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe and accurate diagnostic tool for tumour grading assessment. <i>Journal of Hepatology</i> , 2011, 54, 300-305.	1.8	58
92	Silybin and the liver: From basic research to clinical practice. <i>World Journal of Gastroenterology</i> , 2011, 17, 2288.	1.4	277
93	Plasma antioxidant enzymes and clastogenic factors as possible biomarkers of colorectal cancer risk. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2011, 714, 88-92.	0.4	23
94	Gut Microbiota and Its Pathophysiology in Disease Paradigms. <i>Digestive Diseases</i> , 2011, 29, 518-524.	0.8	50
95	Focal nodular hyperplasia of the liver after intensive treatment for pediatric cancer: is hematopoietic stem cell transplantation a risk factor?. <i>European Journal of Pediatrics</i> , 2011, 170, 807-812.	1.3	20
96	Percutaneous liver biopsy in the clinical management of hepatocellular carcinoma: Back to the future. <i>Hepatology</i> , 2011, 53, 2147-2147.	3.6	0
97	Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 121-136.	1.0	18
98	Autoimmune liver diseases in a paediatric population with coeliac disease – a 10-year single-centre experience. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 253-260.	1.9	42
99	Natural history of gallstone disease: Expectant management or active treatment? Results from a population-based cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 719-724.	1.4	130
100	Development and application of a simple and powerful tool for nutrition and lifestyle education for the Italian general population by general practitioners and family paediatricians. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2009, 2, 139-144.	0.2	2
101	Body weight, lifestyle, dietary habits and gastroesophageal reflux disease. <i>World Journal of Gastroenterology</i> , 2009, 15, 1690.	1.4	138
102	Mesalazine and Rifaximin in Symptomatic Uncomplicated Diverticular Disease. <i>American Journal of Gastroenterology</i> , 2009, 104, 532-532.	0.2	3
103	Development and application of a simple and powerful tool for nutrition and lifestyle education for the Italian general population by general practitioners and family paediatricians. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2009, 2, 139-144.	0.2	6
104	Natural History of Small Gallbladder Polyps Is Benign: Evidence From a Clinical and Pathogenetic Study. <i>American Journal of Gastroenterology</i> , 2009, 104, 624-629.	0.2	32
105	Bacterial flora, gas and antibiotics. <i>Digestive and Liver Disease Supplements</i> , 2009, 3, 54-57.	0.2	1
106	Natural History of Small Gallbladder Polyps Is Benign. <i>American Journal of Gastroenterology</i> , 2009, 104, 624-629.	0.2	7
107	Transjugular intrahepatic portosystemic shunt: A case report of rescue management of unrestrainable variceal bleeding in a pregnant woman. <i>Digestive and Liver Disease</i> , 2008, 40, 387-390.	0.4	29
108	Proton pump inhibitors in cirrhosis: Tradition or evidence based practice?. <i>World Journal of Gastroenterology</i> , 2008, 14, 2980.	1.4	64

#	ARTICLE	IF	CITATIONS
109	Incidence of gallstone disease in Italy: Results from a multicenter, population-based Italian study (the Tj ETQq1 1 0,784314 rgBT /Overl 1.4	1.4	51
110	Effects of Combined IFN-Alpha/Ribavirin Treatment in HCV Disease-Related Progression. , 2008, , 215-236.		0
111	Clinical Efficacy and Effectiveness of Ursodeoxycholic Acid in Cholestatic Liver Diseases. Current Clinical Pharmacology, 2007, 2, 155-177.	0.2	49
112	Diagnostic Effectiveness of Serum Bile Acids in Liver Diseases as Evaluated by Multivariate Statistical Methods. Hepatology, 2007, 3, 707-713.	3.6	73
113	Biliary symptoms, gallbladder motility, and cholecystectomy. Hepatology, 2007, 45, 259-260.	3.6	0
114	Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid. Alimentary Pharmacology and Therapeutics, 2007, 26, 1139-1146.	1.9	41
115	Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease. World Journal of Gastroenterology, 2007, 13, 264.	1.4	91
116	Management of Hepatic Encephalopathy: Focus on Antibiotic Therapy. Digestion, 2006, 73, 94-101.	1.2	45
117	Co-dispensing of contraindicated medications in patients using cisapride in Italy. Pharmacoepidemiology and Drug Safety, 2006, 15, 469-476.	0.9	11
118	A statistical model predicting high hepatocyte proliferation index and the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Alimentary Pharmacology and Therapeutics, 2006, 24, 129-136.	1.9	7
119	Is It Possible to Predict the Clinical Course of Gallstone Disease? Usefulness of Gallbladder Motility Evaluation in a Clinical Setting. American Journal of Gastroenterology, 2006, 101, 2576-2581.	0.2	25
120	Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World Journal of Gastroenterology, 2006, 12, 7239.	1.4	74
121	A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C. Journal of Viral Hepatitis, 2005, 12, 292-299.	1.0	45
122	Helicobacter Pylori Infection Causes Persistent Platelet Activation In Vivo Through Enhanced Lipid Peroxidation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 246-251.	1.1	33
123	Prevalence of gallstone disease in first-degree relatives of patients with cholelithiasis. World Journal of Gastroenterology, 2005, 11, 6508.	1.4	16
124	Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: A prospective study on patients with HCV related cirrhosis. World Journal of Gastroenterology, 2004, 10, 3099.	1.4	38
125	Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obesity Reviews, 2004, 5, 27-42.	3.1	263
126	Use of hormone replacement therapy in Italian women aged 50-70 years. Maturitas, 2004, 49, 241-251.	1.0	22



#	ARTICLE	IF	CITATIONS
127	13 C-methacetin breath test for monitoring hepatic function in cirrhotic patients before and after liver transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 785-790.	1.9	41
128	Ten year incidence of HCV infection in northern Italy and frequency of spontaneous viral clearance. <i>Gut</i> , 2003, 52, 1030-1034.	6.1	59
129	Gastric autoimmune disorders in patients with chronic hepatitis C before, during and after interferon-alpha therapy. <i>World Journal of Gastroenterology</i> , 2003, 9, 1487.	1.4	29
130	Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: Results of an open, controlled trial. <i>World Journal of Gastroenterology</i> , 2003, 9, 1491.	1.4	21
131	The UDCA dosage deficit: a fate shared with CDCA. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 213-216.	0.8	5
132	Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis. <i>Digestive and Liver Disease</i> , 2002, 34, 523-527.	0.4	17
133	Antioxidant properties of ursodeoxycholic acid. <i>Biochemical Pharmacology</i> , 2002, 64, 1661-1667.	2.0	88
134	The Loiano-Monghidoro population-based study of <i>Helicobacter pylori</i> infection: prevalence by 13 C-urea breath test and associated factors. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 1001-1007.	1.9	37
135	Efficacy of ursodeoxycholic acid in association with $\hat{\imath}\pm$ -interferon for chronic hepatitis C in $\hat{\imath}\pm$ -interferon non-responder patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2000, 12, 511-516.	0.8	17
136	Symptoms discriminate irritable bowel syndrome from organic gastrointestinal diseases and food allergy. <i>European Journal of Gastroenterology and Hepatology</i> , 2000, 12, 981-988.	0.8	23
137	13C-Urea Breath Test for <i>Helicobacter pylori</i> Infection: Stability of Samples over Time. <i>Scandinavian Journal of Gastroenterology</i> , 1999, 34, 942-943.	0.6	11
138	Long-Term Results With Interferon Therapy in Chronic Type B Hepatitis: A Prospective Randomized Trial. <i>American Journal of Gastroenterology</i> , 1999, 94, 2246-2250.	0.2	72
139	Sluggish Small Bowel Motility Is Involved in Determining Increased Biliary Deoxycholic Acid in Cholesterol Gallstone Patients. <i>American Journal of Gastroenterology</i> , 1999, 94, 2453-2459.	0.2	25
140	Methylprednisolone administration in primary biliary cirrhosis increases cholic acid turnover, synthesis, and deoxycholate concentration in bile. <i>Digestive Diseases and Sciences</i> , 1999, 44, 2478-2483.	1.1	8
141	Clinical manifestations of gallstone disease: Evidence from the multicenter Italian study on cholelithiasis (MICOL). <i>Hepatology</i> , 1999, 30, 839-846.	3.6	84
142	Dissolution of gallbladder stones with methyl tert-butyl ether and stone recurrence: a European survey. <i>Digestive Diseases and Sciences</i> , 1998, 43, 911-920.	1.1	37
143	Diet and gallstones in Italy: The cross-sectional MICOL results. <i>Hepatology</i> , 1998, 27, 1492-1498.	3.6	70
144	Update on <i>Helicobacter pylori</i> research. <i>European Journal of Gastroenterology and Hepatology</i> , 1997, 9, 613-614.	0.8	5

#	ARTICLE	IF	CITATIONS
145	Antioxidant properties of omeprazole. <i>FEBS Letters</i> , 1996, 382, 189-192.	1.3	67
146	Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. <i>Journal of Hepatology</i> , 1996, 24, 141-147.	1.8	300
147	Alterations of exocrine pancreas in end-stage renal disease do they reflect a clinically relevant uremic pancreopathy?. <i>Digestive Diseases and Sciences</i> , 1995, 40, 2576-2581.	1.1	11
148	Cephalosporins are scavengers of hypochlorous acid. <i>Biochemical Pharmacology</i> , 1995, 49, 1249-1254.	2.0	30
149	Transmural distribution of antioxidant defences and lipid peroxidation in the rabbit left ventricular myocardium. <i>Pflugers Archiv European Journal of Physiology</i> , 1994, 427, 432-436.	1.3	8
150	Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: Gamma GT levels predictive for response. <i>Digestive Diseases and Sciences</i> , 1994, 39, 866-870.	1.1	37
151	Gallstone epidemiology. <i>Current Opinion in Gastroenterology</i> , 1994, 10, 552-557.	1.0	1
152	Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis. <i>Digestive Diseases and Sciences</i> , 1993, 38, 896-902.	1.1	40
153	Rifaximin in the treatment of chronic hepatic encephalopathy; results of a multicenter study of efficacy and safety. <i>Current Therapeutic Research</i> , 1993, 54, 598-609.	0.5	60
154	Erythromycin and gallbladder motor function. <i>Gastroenterology</i> , 1993, 105, 1589.	0.6	2
155	Hepatic uptake and biliary secretion of bile acids in the perfused rat liver. <i>Pharmacological Research</i> , 1992, 25, 51-61.	3.1	4
156	Effect of simvastatin, ursodeoxycholic acid and simvastatin plus ursodeoxycholic acid on biliary lipid secretion and cholic acid kinetics in nonfamilial hypercholesterolemia. <i>Hepatology</i> , 1992, 15, 1072-1078.	3.6	41
157	Comparative evaluation of chenodeoxycholic and ursodeoxycholic acids in obese patients. <i>Gastroenterology</i> , 1991, 101, 490-496.	0.6	28
158	Clinical significance of chronic hyperamylasemia. <i>Digestive Diseases and Sciences</i> , 1991, 36, 1517-1522.	1.1	15
159	Effect of Gemfibrozil Administration on Biliary Lipid Secretion in Hyperlipidemic Patients. <i>Scandinavian Journal of Gastroenterology</i> , 1990, 25, 1227-1234.	0.6	7
160	Gallbladder motility in cholesterol gallstone disease. <i>Gastroenterology</i> , 1990, 99, 1779-1785.	0.6	122
161	Evaluation of the Ileal Absorption Capacity for Bile Acids in the Rabbit. <i>European Surgical Research</i> , 1990, 22, 93-100.	0.6	6
162	Inter and in-tea-observer variation in ultrasonographic detection of gallstones: The Multicenter Italian Study on Epidemiology of Cholelithiasis (M.I.COL.). <i>European Journal of Epidemiology</i> , 1989, 5, 51-57.	2.5	15

#	ARTICLE	IF	CITATIONS
163	Gallstone recurrence after successful oral bile acid treatment. <i>Gastroenterology</i> , 1989, 97, 726-731.	0.6	190
164	A population study on the prevalence of gallstone disease: The sirmione study. <i>Hepatology</i> , 1987, 7, 913-917.	3.6	503
165	Bile acid malabsorption and bile acid diarrhea in intestinal resection. <i>Digestive Diseases and Sciences</i> , 1982, 27, 495-502.	1.1	82
166	Ursodeoxycholic acid vs. chenodeoxycholic acid as cholesterol gallstone-dissolving agents: A comparative randomized study. <i>Hepatology</i> , 1982, 2, 804-810.	3.6	136
167	Effect of chenodiol on the small intestine. Unimpaired structure and function during therapy for gallstone dissolution. <i>JAMA - Journal of the American Medical Association</i> , 1981, 246, 2597-2601.	3.8	0
168	Effect of ursodeoxycholic acid administration on biliary lipid composition and bile acid kinetics in cholesterol gallstone patients. <i>Digestive Diseases and Sciences</i> , 1979, 24, 123-128.	1.1	39
169	The estimation of phospholipids in bile. <i>Clinica Chimica Acta</i> , 1976, 68, 159-166.	0.5	28
170	The Medical Treatment of Cholesterol Gallstones: Experience with Chenodeoxycholic Acid. <i>Digestion</i> , 1976, 14, 209-219.	1.2	69
171	Enzymatic determination of cholesterol in bile. <i>Clinica Chimica Acta</i> , 1975, 64, 337-341.	0.5	161